India markets close in 4 hours 51 minutes
  • BSE SENSEX

    48,188.03
    -356.03 (-0.73%)
     
  • Nifty 50

    14,402.45
    -102.35 (-0.71%)
     
  • USD/INR

    75.2050
    +0.1550 (+0.21%)
     
  • Dow

    33,730.89
    +53.62 (+0.16%)
     
  • Nasdaq

    13,857.84
    -138.26 (-0.99%)
     
  • BTC-INR

    4,745,745.50
    -56,153.50 (-1.17%)
     
  • CMC Crypto 200

    1,373.35
    -2.42 (-0.18%)
     
  • Hang Seng

    28,623.90
    -276.93 (-0.96%)
     
  • Nikkei

    29,639.36
    +18.37 (+0.06%)
     
  • EUR/INR

    90.1312
    +0.1885 (+0.21%)
     
  • GBP/INR

    103.6726
    +0.2768 (+0.27%)
     
  • AED/INR

    20.4480
    +0.0590 (+0.29%)
     
  • INR/JPY

    1.4435
    -0.0051 (-0.35%)
     
  • SGD/INR

    56.3050
    +0.1120 (+0.20%)
     

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

TRACON Pharmaceuticals, Inc.
·2-min read

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:

Investor Contact:

Mark Wiggins

Andrew McDonald

Chief Business Officer

LifeSci Advisors LLC

(858) 251-3492

646-597-6987

mwiggins@traconpharma.com

Andrew@lifesciadvisors.com